Market Place
Sourcing Support
OncoSec Announces $2 Million Registered Direct Offering Under Nasdaq Rules
10 Apr 2023 //
PR NEWSWIRE
OncoSec blindsided as blinded review reveals Keytruda combo flop
04 Apr 2023 //
FIERCE BIOTECH
Penny stock, Merck partner lays off 45% of staff to reach PhII readout by 2023
05 Oct 2022 //
ENDPTS
OncoSec sheds 45% of staff to fund IL-12 through Keytruda trial
05 Oct 2022 //
FIERCEBIOTECH
OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial
08 Jul 2021 //
PHARMABIZ
OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial
08 Jul 2021 //
PHARMABIZ
OncoSec to Present Encore Interim Data from the KEYNOTE-695
16 Apr 2021 //
PRNEWSWIRE
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1
25 Mar 2021 //
ONCOSEC
OncoSec Announces Publication in Clinical Cancer Research of Data Supporting
01 Mar 2021 //
PRNEWSWIRE
OncoSec Strengthens Management Team With Two New Appointments
02 Feb 2021 //
PRNEWSWIRE
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12
28 Jan 2021 //
PRNEWSWIRE
OncoSec doses subjects in Covid-19 vaccine candidate trial
27 Jan 2021 //
CLINICALTRIALSARENA
OncoSec Medical Announces Proposed Public Offering of Common Stock
20 Jan 2021 //
PRNEWSWIRE
OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™
19 Jan 2021 //
PRNEWSWIRE
OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™
19 Jan 2021 //
BIOSPACE
OncoSec Announces Publication in International Journal of Surgery Case Reports
04 Dec 2020 //
PRNEWSWIRE
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in at SITC 2020
09 Nov 2020 //
PRNEWSWIRE
Qualigen Engages STA Pharmaceutical as GMP Manufacturer of AS1411
05 Nov 2020 //
PRNEWSWIRE
OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial
03 Nov 2020 //
PRESS RELEASE
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1
29 Oct 2020 //
ONCOSEC
OncoSec Announces Issuance of New US Patent Expanding Coverage of TAVO
06 Oct 2020 //
PRESSRELEASE
OncoSec initiates phase 2 study of Tavo in combo with Opdivo to treat patient
28 Aug 2020 //
PHARMABIZ
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at (AACR)
22 Jun 2020 //
PRESS RELEASE
OncoSec Expands KEYNOTE-890 Trial into First-Line (mTNBC) with TAVO™
09 Jun 2020 //
PRESS RELEASE
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS
21 May 2020 //
PR NEWSWIRE
OncoSec Receives $850,000 from The Australian R&D Tax Incentive Program
10 Mar 2020 //
PR NEWSWIRE
OncoSec Announces Closing of the CGP/Sirtex Transaction
10 Feb 2020 //
BUSINESSWIRE
Sirtex Medical Announces Closing of Strategic Transaction with OncoSec Medical
10 Feb 2020 //
PR NEWSWIRE
OncoSec Announces Closing of the CGP/Sirtex Transaction
10 Feb 2020 //
BUSINESSWIRE
Sirtex Medical Announces Closing of Strategic Transaction with OncoSec Medical
10 Feb 2020 //
PR NEWSWIRE
OncoSec Secures Phesi ClinSiteâ„¢ License
23 Jan 2020 //
BUSINESS WIRE
OncoSec Releases Benefits of Proposed CGP/Sirtex Transaction and Partnership
20 Dec 2019 //
BUSINESSWIRE
OncoSec Disputes Alpha Holdings` Claims Regarding Pending Acquisition from CGP
02 Dec 2019 //
BIOSPACE
